Target RWE announces biorepository Precision Medicine Platform to advance real-world evidence in liver disease and immune-mediated inflammatory conditions in dermatology and gastroenterology

Target RWE introduces Precision Medicine Platform biorepository of more than 150,000 samples from over 10,000 patients to complement its longitudinal clinical real-world data registries for real-world evidence insights in liver disease and immune-mediated inflammatory conditions in dermatology and gastroenterology.

On Jan 4, 2024, Target RWE – one of the largest providers of real-world evidence (RWE) in non-cancer conditions – announced its formation of a new Precision Medicine Platform: a biorepository of over 150,000 samples collected along the patient journey of more than 10,000 individuals, with more than 5 years of clinical follow-up. Genetic and biomarker information from the novel platform will combine synergistically with Target RWE’s expanding longitudinal clinical real-world data (RWD) registries to advance generation of RWE insights to understand disease progression and address unmet medical need within the company’s foci of liver disease and immune-mediated inflammatory conditions in dermatology and gastroenterology.

Target RWE focuses on disease areas with high unmet medical needs and emerging therapies, including liver disease, metabolic dysfunction-associated steatohepatitis (MASH, formerly known as non-alcoholic steatohepatitis, NASH), and immune-mediated inflammatory conditions in dermatology and gastroenterology. For the new biorepository Precision Medicine Platform, bio-samples including serum, whole blood, plasma and skin tape strips have been collected from patients enrolled through TARGET RWE’s observational studies (e.g. TARGET-LD, TARGET-NASH, TARGET-IBD, and TARGET-DERM.)

Within just the TARGET-NASH registry, more than 80,000 biospecimen samples have been collected. These comprise an average of four samples per patient, at various time points before and after a disease progression, defining events over 74 months of clinical follow-up. Patient-reported outcomes have also been gathered at multiple time points of the patient journey.

The Precision Medicine Platform biorepository samples can be linked to Target RWE’s series of longitudinal clinical RWD registries, across multiple therapeutic areas, to connect clinical outcomes and disease progression status. The platform offers the potential of being instrumental in genetic and biomarker identification for patient populations with rapid disease progression or regarding prediction of treatment response. Target RWE also provides advanced, interactive analytics to extract deep RWE insights from RWD.

“It is exciting to be a part of an organization with clinically rich, RWD complete with genomic information that enables clients to generate meaningful insights that aim to improve patient outcomes,” said Jennifer Christian, PharmD, PhD, FISPE, Chief Scientific Officer of Target RWE. “Our data are backed by a scalable, high-data curation engine and an epidemiology team that applies robust, principled statistical methods that can deliver actionable evidence and guide drug development.”

“Our Platform paired with Target RWE’s predictive analytics capabilities brings next-level sophistication to research design and implementation. Partners can access the biorepository samples for analyses including biomarker characterizations, diagnostic assay development, and validation, sequencing, and genotyping,” said Derek Evans, Target RWE CEO. “This is just one example of how we have led the industry with innovative thinking and solutions that translate to meaningful research outcomes for our partners.”

Target RWE shared its newest data from the TARGET-NASH registry at the NASH-TAG annual conference in Utah, January 4–6, 2024. Poster topics included non-invasive tests as a prediction tool to assess MASH resolution score and longitudinal assessment of cardiovascular risk for NASH/MASH patients.